TOP TEN perturbations for 39288_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39288_at
Selected probe(set): 211677_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39288_at (211677_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
Li-Fraumeni syndrome study 2 / normal breast stromal cell sample
Relative Expression (log2-ratio):-2.2364216Number of Samples:8 / 4
| Experimental | Li-Fraumeni syndrome study 2 |
| Morphologically normal breast stromal cells were isolated from non-involved tissue of Li-Fraumeni syndrome patients with breast cancer. Li-Fraumeni syndrome is cancer predisposing syndrome caused by germline mutation of the p53. Clinical characteristics of patient (50): 31-years old female with breast cancer and p53 mutation at codon 133 in exon 5, in one of the two alleles (Met133Thr). The donor had also family history of breast cancer and p53 mutations through at least last three generations. Clinical characteristic of patient (IUSM): 29-years old Caucasian female with non-invasive ductal carcinoma and bilateral Paget disease of the nipples; with heterozygous p53 12141delG germline frameshift mutation. The donor had also a maternal aunt with bilateral breast cancer in her 30's and a male sibling with osteogenic sarcoma of a leg at age 13, who later died of a brain tumor at age 19. | |
| Control | normal breast stromal cell sample |
| Normal breast stromal cells were isolated from donor with no history of cancer and wild-type p53. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):1.9724703Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue
Relative Expression (log2-ratio):-1.8786755Number of Samples:20 / 9
| Experimental | atypical teratoid/rhabdoid tumor study 1 |
| Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT). | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)
Relative Expression (log2-ratio):1.8517523Number of Samples:6 / 10
| Experimental | diphenylcyclopropenone study 1 (late) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
| Control | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (intermediate)
Relative Expression (log2-ratio):1.8094416Number of Samples:6 / 10
| Experimental | diphenylcyclopropenone study 1 (late) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
| Control | diphenylcyclopropenone study 1 (intermediate) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 14 days. ATC code:--- |
stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)
Relative Expression (log2-ratio):1.7721443Number of Samples:2 / 2
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | stem cell differentiation study 41 (hES-T3 EB) |
| Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype. |
psoriasis study 20 (lesional) / psoriasis study 20 (non-lesional)
Relative Expression (log2-ratio):-1.7580175Number of Samples:4 / 4
| Experimental | psoriasis study 20 (lesional) |
| Lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia preferentially near the central region of active plaques, except in cases where the center was poorly defined due to an irregular boundary. Regions near the edge of individual plaques were avoided to ensure that uninvolved skin was not included. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C. | |
| Control | psoriasis study 20 (non-lesional) |
| Non-lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia from the buttocks and at least 10 cm away from the nearest active psoriasis plaque. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C. |
diphenylcyclopropenone study 1 (early) / placebo treated skin tissue
Relative Expression (log2-ratio):-1.7446442Number of Samples:10 / 11
| Experimental | diphenylcyclopropenone study 1 (early) |
| Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- | |
| Control | placebo treated skin tissue |
| Skin biopsy samples of healthy volunteers exposed to placebo for 3 days. |
atopic dermatitis study 21 (lesional; dermis) / normal dermis tissue
Relative Expression (log2-ratio):-1.5591898Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; dermis) |
| Lesional dermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal dermis tissue |
| Dermal samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):1.5519419Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |